Feed excerpt — reported by STAT News
Novo Nordisk's ZEUS trial showed ziltivekimab lowered key inflammation biomarkers but failed to reduce serious cardiovascular events in high-risk patients.
MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →